Jorge Monge: It Was An Honor to Take Part in the 3rd EBA Workshop on Rare Blood Provision
Jorge Monge, Head of Immunohematology Lab. Basque Center for Blood Transfusion and Human Tissues (Osakidetza), shared on LinkedIn:
”Twenty years of the Spanish program for rare blood donors.
It was an honor to take part in the 3rd EBA Workshop on Rare Blood Provision, organized by the European Blood Alliance (EBA) in collaboration with the International Society of Blood Transfusion (ISBT) and Osakidetza.
In my presentation — “Twenty years of the Spanish program for rare blood donors” — I shared the journey, achievements, and lessons learned from two decades of building and developing this national program managed within the Sociedad Española de Transfusión Sanguínea (SETS) and coordinated by Eduardo Muñiz.
It’s been a collective effort, made possible thanks to the dedication of professionals across Spain who work every day to support patients with rare blood needs.
If you couldn’t attend, you can now watch my talk here:
- Twenty years of the Spanish program for rare blood donors
And I highly recommend exploring the other inspiring talks from the workshop:
- Rare Blood Provision Workshop”
Stay updated with Hemostasis Today.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis